Search

Your search keyword '"Fifi-Mah, Aurore"' showing total 41 results
Start Over Author "Fifi-Mah, Aurore"
41 results on '"Fifi-Mah, Aurore"'

5. Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

Author

Hoa, Sabrina, Laaouad, Linda, Roberts, Janet, Ennis, Daniel, Ye, Carrie, Al Jumaily, Karam, Pope, Janet, Nevskaya, Tatiana, Saltman, Alexandra, Himmel, Megan, Rottapel, Robert, Ly, Christina, Colmegna, Ines, Fifi-Mah, Aurore, Maltez, Nancy, Tisseverasinghe, Annaliese, Hudson, Marie, and Jamal, Shahin

Published
2021
Full Text
View/download PDF

9. An Environmental Scan and Appraisal of Patient Online Resources for Managing Rheumatoid Arthritis Flares

Author

Subdar, Shakeel, primary, Hoens, Alison M., additional, White, Krista, additional, Hartfeld, Nicole M.S., additional, Dhiman, Kiran, additional, Duffey, Keeva, additional, Heath, Claire E., additional, Lamoureux, Gisele, additional, Graveline, Christine, additional, Davidson, Eileen, additional, Hazlewood, Glen, additional, Lacaille, Diane, additional, Lopatina, Elena, additional, Barber, Megan R.W., additional, Then, Karen L., additional, Crump, Trafford, additional, Zafar, Saania, additional, Manske, Sarah L., additional, Charlton, Alexandra, additional, Osinski, Kelly, additional, Fifi-Mah, Aurore, additional, Mosher, Dianne, additional, and Barber, Claire E.H., additional

Published
2024
Full Text
View/download PDF

10. Investigating the influence of patient eligibility characteristics on the number of deferrable rheumatologist visits: planning for a patient-initiated follow-up (PIFU) strategy.

Author

Subdar, Shakeel, primary, Dhiman, Kiran, additional, Hartfeld, Nicole M.S., additional, Hoens, Alison M., additional, White, Krista, additional, Manske, Sarah L., additional, Hazlewood, Glen, additional, Lacaille, Diane, additional, Lopatina, Elena, additional, Barber, Megan R.W., additional, Mosher, Dianne, additional, Fifi-Mah, Aurore, additional, Twilt, Marinka, additional, Luca, Nadia, additional, Then, Karen L., additional, Crump, Trafford, additional, Zafar, Saania, additional, Osinski, Kelly, additional, and Barber, Claire E.H., additional

Published
2024
Full Text
View/download PDF

11. Non-invasive biomarkers of disease activity and organ damage in ANCA-associated vasculitis: a systematic review

Author

Renson, Thomas, primary, Kelly, Margaret M, additional, Benediktsson, Hallgrimur, additional, Grundhoefer, Nele, additional, Luca, Nadia, additional, Miettunen, Paivi, additional, Twilt, Marinka, additional, Grisaru, Silviu, additional, Wade, Andrew, additional, Banks, Anke, additional, Fifi-Mah, Aurore, additional, Hamiwka, Lorraine, additional, and Benseler, Susanne, additional

Published
2024
Full Text
View/download PDF

12. Investigating the Influence of Patient Eligibility Characteristics on the Number of Deferrable Rheumatologist Visits: Planning for a Patient-Initiated Follow-Up Strategy.

Author

Subdar, Shakeel, Dhiman, Kiran, Hartfeld, Nicole M. S., Hoens, Alison M., White, Krista, Manske, Sarah L., Hazlewood, Glen, Lacaille, Diane, Lopatina, Elena, Barber, Megan R. W., Mosher, Dianne P., Fifi-Mah, Aurore, Twilt, Marinka, Luca, Nadia, Then, Karen L., Crump, Trafford, Zafar, Saania, Osinski, Kelly, and Barber, Claire E. H.

Published
2024
Full Text
View/download PDF

13. Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Health Service Improvements

Author

Thomas, Megan, primary, Barnabe, Cheryl, additional, Kleissen, Tessa, additional, Lacaille, Diane, additional, Hazlewood, Glen, additional, Fifi‐Mah, Aurore, additional, Hassen, Nejat, additional, Henry, Richard, additional, Kuluva, Michael, additional, English, Kelly, additional, Koehn, Cheryl, additional, Lane, Therese, additional, and Johnson, Nicole, additional

Published
2023
Full Text
View/download PDF

17. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum

Author

Turgeon, David, primary, Bakowsky, Volodko, additional, Baldwin, Corisande, additional, Cabral, David A, additional, Clements-Baker, Marie, additional, Clifford, Alison, additional, Cohen Tervaert, Jan Willem, additional, Dehghan, Natasha, additional, Ennis, Daniel, additional, Famorca, Leilani, additional, Fifi-Mah, Aurore, additional, Girard, Louis-Philippe, additional, Lefebvre, Frédéric, additional, Liang, Patrick, additional, Makhzoum, Jean-Paul, additional, Massicotte-Azarniouch, David, additional, Mendel, Arielle, additional, Milman, Nataliya, additional, Reich, Heather N, additional, Robinson, David B, additional, Ross, Carolyn, additional, Rumsey, Dax G, additional, Soowamber, Medha, additional, Towheed, Tanveer E, additional, Trudeau, Judith, additional, Twilt, Marinka, additional, Yacyshyn, Elaine, additional, Yardimci, Gozde K, additional, Khalidi, Nader, additional, Barra, Lillian, additional, and Pagnoux, Christian, additional

Published
2023
Full Text
View/download PDF

18. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis

Author

Grayson, Peter, Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Craven, Anthea, Judge, Andrew, Khalid, Sara, Luqmani, Raashid, Watts, Richard, Merkel, Peter, Hutchings, Andrew, Grayson, Peter C., Luqmani, Raashid A., Merkel, Peter A., Gatenby, Paul, Watts, Richard A., Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, Dhindsa, Navjot, Fifi-Mah, Aurore, Khalidi, Nader, Liang, Patrick, Milman, Nataliya, Pineau, Christian, Tian, Xinping, Wang, Guochun, Wang, Tian, Zhao, Ming hui, Tesar, Vladimir, Baslund, Bo, Hammam, Nevin, Shahin, Amira, Pirila, Laura, Putaala, Jukka, Hellmich, Bernhard, Henes, Jörg, Lamprecht, Peter, Neumann, Thomas, Schmidt, Wolfgang, Sunderkoetter, Cord, Szekanecz, Zoltan, Danda, Debashish, Das, Siddharth, Gupta, Rajiva, Rajasekhar, Liza, Dobashi, Hiroaki, Sharma, Aman, Wagh, Shrikant, Clarkson, Michael, Kawakami, Tamihiro, Kobayashi, Shigeto, Kono, Hajime, Makino, Hirofumi, Matsui, Kazuo, Muso, Eri, Suzuki, Kazuo, Ikeda, Kei, Takeuchi, Tsutomu, Tsukamoto, Tatsuo, Uchida, Shunya, Wada, Takashi, Yamada, Hidehiro, Yamagata, Kunihiro, Yumura, Wako, Lai, Kan Sow, Flores-Suarez, Luis Felipe, Hinojosa, Andrea, Rutgers, Bram, Tak, Paul Peter, Grainger, Rebecca, Quincey, Vicki, Stamp, Lisa, Besada, Emilio, Diamantopoulos, Andreas, Sznajd, Jan, Azevedo, Elsa, Geraldes, Ruth, Rodrigues, Miguel, Santos, Ernestina, Song, Yeong Wook, Moiseev, Sergey, Hocˇevar, Alojzija, Arimura, Yoshihiro, Cid, Maria Cinta, Moreno, Xavier Solanich, Atukorala, Inoshi, Berglin, Ewa, Molloy, Eamonn, Salvarani, Carlo, Schiavon, Franco, Tombetti, Enrico, Vaglio, Augusto, Amano, Koichi, Fujimoto, Shouichi, Harigai, Masayoshi, Hirano, Fumio, Hirahashi, Junichi, and Honma, Sakae

Abstract

Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1 × 109/liter (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1), and hematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% confidence interval [95% CI] 77–91%) and the specificity was 99% (95% CI 98–100%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research.

Published
2022

22. CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update

Author

Mendel, Arielle, primary, Ennis, Daniel, additional, Go, Ellen, additional, Bakowsky, Volodko, additional, Baldwin, Corisande, additional, Benseler, Susanne M., additional, Cabral, David A., additional, Carette, Simon, additional, Clements-Baker, Marie, additional, Clifford, Alison H., additional, Cohen Tervaert, Jan Willem, additional, Cox, Gerard, additional, Dehghan, Natasha, additional, Dipchand, Christine, additional, Dhindsa, Navjot, additional, Famorca, Leilani, additional, Fifi-Mah, Aurore, additional, Garner, Stephanie, additional, Girard, Louis-Philippe, additional, Lessard, Clode, additional, Liang, Patrick, additional, Noone, Damien, additional, Makhzoum, Jean-Paul, additional, Milman, Nataliya, additional, Pineau, Christian A., additional, Reich, Heather N., additional, Rhéaume, Maxime, additional, Robinson, David B., additional, Rumsey, Dax G., additional, Towheed, Tanveer E., additional, Trudeau, Judith, additional, Twilt, Marinka, additional, Yacyshyn, Elaine, additional, Yeung, Rae S.M., additional, Barra, Lillian B., additional, Khalidi, Nader, additional, and Pagnoux, Christian, additional

Published
2020
Full Text
View/download PDF

24. ANCA Vasculitis and Hemophagocytic Lymphohistiocytosis following a Fecal Microbiota Transplant

Author

Amlani, Adam, Bromley, Amy, and Fifi-Mah, Aurore

Subjects
030203 arthritis & rheumatology, Liver injury, medicine.medical_specialty, Hemophagocytic lymphohistiocytosis, lcsh:Diseases of the musculoskeletal system, medicine.diagnostic_test, business.industry, Hypertriglyceridemia, Case Report, Glomerulonephritis, Antisynthetase syndrome, General Medicine, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Cholestasis, 030225 pediatrics, Liver biopsy, Internal medicine, medicine, lcsh:RC925-935, business, Vasculitis
Abstract

A 69-year-old female with antisynthetase syndrome, a history of multiple recurrent infections, and documented previous negative titres for anti-neutrophil cystoplasmic antibody (ANCA) suddenly developed a de novo MPO-ANCA-associated glomerulonephritis three weeks after a fecal microbiota transplantation (FMT) for recurrent Clostridium difficile infections. Six months following her FMT and less than two weeks following treatment for urosepsis, she developed severe cholestasis, a markedly elevated ferritin and hypertriglyceridemia. An initial liver biopsy was suggestive of drug-induced liver injury and thus she was treated with supportive care. After she failed to improve, a second liver biopsy supported the diagnosis of hemophagocytic lymphohistiocytosis (HLH). This case highlights difficulties surrounding the early diagnosis of HLH and also questions the role of FMT and/or recurrent infections as a trigger for ANCA-associated vasculitis.

Published
2018
Full Text
View/download PDF

26. CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update.

Author

Mendel, Arielle, Ennis, Daniel, Go, Ellen, Bakowsky, Volodko, Baldwin, Corisande, Benseler, Susanne M., Cabral, David A., Carette, Simon, Clements-Baker, Marie, Clifford, Alison H., Tervaert, Jan Willem Cohen, Cox, Gerard, Dehghan, Natasha, Dipchand, Christine, Dhindsa, Navjot, Famorca, Leilani, Fifi-Mah, Aurore, Garner, Stephanie, Girard, Louis-Philippe, and Lessard, Clode

Published
2021
Full Text
View/download PDF

28. CS-36 Recommendations for the assessment of systemic lupus erythematosus in canada

Author

Keeling, Stephanie, primary, Alabdurubalnabi, Zainab, additional, Avina-Zubieta, Antonio, additional, Barr, Susan, additional, Bergeron, Louise, additional, Bernatsky, Sasha, additional, Bourre-Tessier, Josiane, additional, Clarke, Ann, additional, Baril-Dionne, Alexandra, additional, Dutz, Jan, additional, Ensworth, Stephanie, additional, Fifi-Mah, Aurore, additional, Fortin, Paul R, additional, Gladman, Dafna, additional, Haaland, Derek, additional, Hanly, John G, additional, Hiraki, Linda T, additional, Hussein, Sara, additional, Legault, Kimberly, additional, Levy, Deborah, additional, Lim, Lily, additional, Matsos, Mark, additional, McDonald, Emily G, additional, Medina-Rosas, Jorge, additional, Pardi, Jordi Pardo, additional, Peschken, Christine, additional, Pineau, Christian, additional, Pope, Janet, additional, Rader, Tamara, additional, Reynolds, Jen, additional, Silverman, Earl, additional, Tselios, Konstantinos, additional, Suitner, Manon, additional, Urowitz, Murray, additional, Touma, Zahi, additional, Vinet, Evelyne, additional, and Santesso, Nancy, additional

Published
2018
Full Text
View/download PDF

32. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.

Author

Keeling, Stephanie O., Alabdurubalnabi, Zainab, Avina-Zubieta, Antonio, Barr, Susan, Bergeron, Louise, Bernatsky, Sasha, Bourre-Tessier, Josiane, Clarke, Ann, Baril-Dionne, Alexandra, Dutz, Jan, Ensworth, Stephanie, Fifi-Mah, Aurore, Fortin, Paul R., Gladman, Dafna D., Haaland, Derek, Hanly, John G., Hiraki, Linda T., Hussein, Sara, Legault, Kimberly, and Levy, Deborah

Published
2018
Full Text
View/download PDF

34. Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire

Author

Famorca, Leilani, primary, Twilt, Marinka, additional, Barra, Lillian, additional, Bakowsky, Volodko, additional, Benseler, Susanne, additional, Cabral, David, additional, Carette, Simon, additional, Dhindsa, Navjot, additional, Fifi-Mah, Aurore, additional, Goulet, Michelle, additional, Khalidi, Nader, additional, Khraishi, Majed, additional, McGeoch, Lucy, additional, Milman, Nataliya, additional, Pineau, Christian, additional, Shojania, Kam, additional, Taylor-Gjevre, Regina, additional, Towheed, Tanveer, additional, Trudeau, Judith, additional, Yacyshyn, Elaine, additional, Liang, Patrick, additional, and Pagnoux, Christian, additional

Published
2015
Full Text
View/download PDF

35. CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides – Executive Summary

Author

McGeoch, Lucy, primary, Twilt, Marinka, additional, Famorca, Leilani, additional, Bakowsky, Volodko, additional, Barra, Lillian, additional, Benseler, Susan, additional, Cabral, David A., additional, Carette, Simon, additional, Cox, Gerald P., additional, Dhindsa, Navjot, additional, Dipchand, Christine, additional, Fifi-Mah, Aurore, additional, Goulet, Michele, additional, Khalidi, Nader, additional, Khraishi, Majed M., additional, Liang, Patrick, additional, Milman, Nataliya, additional, Pineau, Christian A., additional, Reich, Heather, additional, Samadi, Nooshin, additional, Shojania, Kam, additional, Taylor-Gjevre, Regina, additional, Towheed, Tanveer E., additional, Trudeau, Judith, additional, Walsh, Michael, additional, Yacyshyn, Elaine, additional, and Pagnoux, Christian, additional

Published
2015
Full Text
View/download PDF

37. CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides.

Author

McGeoch, Lucy, Twilt, Marinka, Famorca, Leilani, Bakowsky, Volodko, Barra, Lillian, Benseler, Susan M., Cabral, David A., Carette, Simon, Cox, Gerald P., Dhindsa, Navjot, Dipchand, Christine S., Fifi-Mah, Aurore, Goulet, Michelle, Khalidi, Nader, Khraishi, Majed M., Liang, Patrick, Milman, Nataliya, Pineau, Christian A., Reich, Heather N., and Samadi, Nooshin

Published
2016
Full Text
View/download PDF

38. GRADE-Based Recommendations for the Diagnosis and Monitoring of Systemic Lupus Erythematosus in Canada

Author

Keeling, Stephanie, Alabdurubalnabi, Zainab, Avina-Zubieta, J. Antonio, Barr, Susan, Bergeron, Louise, Bernatsky, Sasha, Bourre-Tessier, Josiane, Clarke, Ann E., Baril-Dionne, Alexandra, Dutz, Jan, Ensworth, Stephanie, Fifi-Mah, Aurore, Fortin, Paul R., Gladman, Dafna D., Haaland, Derek, Hanly, John G., Hiraki, Linda T., Hussein, Sara, Legault, Kimberly, Levy, Deborah M., Lim, Lily, Matsos, Mark, Mcdonald, Emily, Medina-Rosas, Jorge, Pardo, Jordi Pardo, Peschken, Christine A., Pineau, Christian, Pope, Janet E., Rader, Tamara, Reynolds, Jennifer, Silverman, Earl, Suitner, Manon, Tselios, Konstantinos, Urowitz, Murray, Zahi Touma, Vinet, Evelyne, and Santesso, Nancy

39. The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO): The Development of a National Collaboration for Research, Advocacy, Education and Optimizing Patient Care in an Emerging and Complex Domain

Author

Arreola, Lourdes, Hudson, Marie, Ye, Carrie, Roberts, Janet, Fifi-Mah, Aurore, Appleton, Tom, Colmegna, Ines, Dutz, Jan, Ennis, Daniel, Fritzler, Marvin, Choi, May, Himmel, Megan, Hoa, Sabrina, Maltez, Nancy, Janet Pope, Rottapel, Robert, Saltman, Alexandra, Tisseverasinghe, Annaliese, and Jamal, Shahin

40. Impact of Age on Rheumatic Immune-related Adverse Events: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO).

Author

Li J, Hudson M, Ye C, Roberts J, Fifi-Mah A, Choi MY, Hoa S, Appleton CT, Pope J, Maltez N, Arreola LG, Obrzut A, and Jamal S

Abstract

Objective: Immune checkpoint inhibitors (ICI) have revolutionized cancer outcomes but are limited by immunerelated adverse events (irAE), including rheumatic irAEs (Rh-irAE). Aging is associated with increased inflammation, referred to as "inflamm-aging". In this study, we explore the impact of age on severity, frequency, and treatment of Rh-irAEs., Methods: Adults with new Rh-irAEs after ICI exposure are followed prospectively across 10 Canadian sites as part of the CanRIO prospective cohort. In this study of patients seen between January 2020 and March 2023, we compare the severity of Rh-irAE and number of irAE between patients ≥65 years and <65 years and explore potential epidemiologic, treatment-related, and phenotypic differences between the older and younger patients., Results: A total of 139 patients with de novo Rh-irAEs were included, 58 in the "younger" (<65 years) and 81 in the "older" (≥65 years) group. There were no significant differences in severity of Rh-irAE (p=0.84) or number of irAEs (p=0.21), although there was a non-significant trend towards more older patients than younger patients with ≥3 irAEs (24% vs. 14%). Types of treatment for Rh-irAEs were similar between the groups. ICI continuation did not differ. Within the ICI-inflammatory arthritis (ICI-IA) subgroup, there was also no significant difference in the incidence of severe Rh-irAEs (p=0.51)., Conclusion: Similar numbers of overall irAE and severity of Rh-irAE were observed between older vs. younger patients who developed Rh-irAE after treatment with ICI therapy, suggesting that "inflamm-aging" does not play a significant role in Rh-irAEs. Larger studies are needed to explore potential differences in patient phenotypes.

Published
2024
Full Text
View/download PDF

41. Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey.

Author

Barra L, Liang P, Benseler SM, Cabral DA, Fifi-Mah A, Li Y, Milman N, Twilt M, Yacyshyn E, and Pagnoux C

Abstract

Objective: Takayasu arteritis (TAK) is a large vessel vasculitis that predominately affects young women and can cause severe ischemic complications. Given the rarity of TAK, the management of this condition is challenging. We aim to describe current rheumatologist practices for the management of TAK and identify discrepancies and gaps in knowledge., Methods: An online survey (developed by the Canadian Vasculitis Network and approved by the Canadian Rheumatology Association) containing 48 questions with regard to the diagnosis, monitoring and treatment of TAK was distributed to 495 Canadian adult and pediatric rheu-matologists by email., Results: Sixty-six rheumatologists completed the survey (13% response rate): the majority (73%) were from academic centers and ≤25% reported managing more than ten patients in their career. For establishing the diagnosis of TAK, they relied on a combination of signs and symptoms of ischemia, elevations of inflammatory markers and vascular imaging (typically computed tomography and magnetic resonance angiography). The frequency of monitoring for disease activity and the methods employed (clinical, laboratory or imaging) were variable. All physicians used corticosteroids for the treatment of TAK, but 42% would treat for at least 6-12 months, 26% for 12-24 months and 23% would never stop corticosteroids. Fifty-three percent would always use an immunosuppressant (most commonly methotrexate or azathioprine) in addition to corticosteroids and the remainder would only start an immunosuppressant in patients with refractory or relapsing disease., Conclusion: Physician practices for the management of TAK are variable, suggesting that there are knowledge gaps, which may impact outcomes in patients with TAK., Competing Interests: Disclosure The authors report no conflicts of interest in this work.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results